Sarilumab
Brand name: Kevzara
Rank #339 of 500 drugs by total cost
$30.5M
Total Cost
6,822
Total Claims
$30.5M
Total Cost
331
Prescribers
$4,466
Cost per Claim
149
Beneficiaries
7,093
30-Day Fills
$92K
Avg Cost/Provider
21
Avg Claims/Provider
About Sarilumab
Sarilumab (sold as Kevzara) was prescribed 6,822 times by 331 Medicare Part D providers in 2023, costing the program $30.5M. At $4,466 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 336 | Diphth,pertuss(Acell),tet Vac (Boostrix Tdap) | $31.2M | 466,555 |
| 337 | Tafamidis Meglumine (Vyndaqel) | $31.0M | 1,387 |
| 338 | Midodrine Hcl (Midodrine Hcl) | $30.9M | 383,390 |
| 339 | Sarilumab (Kevzara) | $30.5M | 6,822 |
| 340 | Dabrafenib Mesylate (Tafinlar) | $30.4M | 2,377 |
| 341 | Testosterone (Testosterone) | $30.4M | 131,549 |
| 342 | Hydroxyzine Hcl (Hydroxyzine Hcl) | $30.2M | 1,474,936 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology